Evidence map›Paper›PMID 37417029›Full record

ReviewAnnals of African medicine

COVID-19 in hematological malignancies: Case series and literature review.

Sunday Ocheni, Theresa Ukamaka Nwagha, Nneka Amu, Onochie Ikenna Obodo, Kelechi Okereke, Kelechi Chikezie, C S Ejezie, Gladys Udoka Ilechukwu, Chiemelie Obiatuegwu

Open access · greenAbstract readReviewCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of African medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sunday OcheniDepartment of Haematology and Immunology, University of Nigeria; Department of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria.
Theresa Ukamaka NwaghaDepartment of Haematology and Immunology, University of Nigeria; Department of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria.
Nneka AmuDepartment of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria.
Onochie Ikenna ObodoDepartment of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria.
Kelechi OkerekeDepartment of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria.
Kelechi ChikezieDepartment of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria.
C S EjezieDepartment of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria.
Gladys Udoka IlechukwuDepartment of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria.
Chiemelie ObiatuegwuDepartment of Haematology and Immunology, University of Nigeria Teaching Hospital, Ituku-Ozalla Campus, Enugu, Nigeria.
University of Nigeria Teaching Hospital · NGUniversity of Nigeria · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Earlier reports suggest that cancer patients were twice more likely to contract severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this report, we describe two patients with hematological malignancies seen at the peak of the first wave of the coronavirus disease 2019 pandemic. A 61-year-old man was referred to our urology unit he was diagnosed with nodular hyperplasia and multiple myeloma and commenced on bortezomib, thalidomide, and dexamethasone combination chemotherapy. He developed a cough and fever, with SPO

Indexed as

COVID-19Hematologic NeoplasmsDacarbazineHumansInfantMaleMiddle AgedPandemicsSARS-CoV-2DacarbazineCancer treatmenthematological malignanciesimmunosuppressionsevere acute respiratory syndrome coronavirus 2

Identifiers

PMID37417029
PMCPMC10445697
OpenAlexW4383480693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.